PMID- 21084799
OWN - NLM
STAT- MEDLINE
DCOM- 20110103
LR  - 20231213
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 37
IP  - 11
DP  - 2010 Nov
TI  - [RNA interference for cancer therapies].
PG  - 2033-41
AB  - RNA interference (RNAi) is a phenomenon of sequence-specific gene silencing in 
      mammalian cells and its discovery has lead to its wide application as a powerful 
      tool in post-genomic research. Recently, short interfering RNA (siRNA), which 
      induces RNAi, has been experimentally introduced as a cancer therapy and is 
      expected to be developed as a nucleic acid-based medicine. Selection of 
      appropriate gene targets is an important parameter in the potential success of 
      siRNA cancer therapies. Candidate targets include genes associated with cell 
      proliferation, metastasis, angiogenesis, and drug resistance. Importantly, 
      silencing of such genes must not affect the functions of normal cells. 
      Development of suitable drug delivery systems (DDSs) is also an important issue. 
      Numerous methods to transfect siRNAs into cells have been developed, and the use 
      of non-viral DDSs is preferred because it offers greater safety for clinical 
      application than does the use of viral DDSs. In this article, we briefly review 
      the mechanism of RNAi and non-viral DDSs. Next, we discuss some of the most 
      recent findings concerning the administration of siRNAs against polo-like 
      kinase-1 (PLK-1), which regulates the mitotic process in mammalian cells. 
      Finally, several current clinical trials of RNAi therapies against cancers are 
      discussed. Results of current studies and clinical trials demonstrate that 
      manipulation of the RNAi mechanism by use of targeted siRNA offers a novel and 
      attractive therapeutic option against cancer.
FAU - Ashihara, Eishi
AU  - Ashihara E
AD  - Department of Molecular Cell Physiology, Kyoto Prefectural University of Medicine 
      and Department of Transfusion Medicine and Cell Therapy, Kyoto University 
      Hospital, Kyoto, Japan.
LA  - jpn
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (RNA, Small Interfering)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Cell Cycle Proteins
MH  - Drug Delivery Systems
MH  - Humans
MH  - Neoplasms/drug therapy
MH  - Protein Serine-Threonine Kinases
MH  - Proto-Oncogene Proteins
MH  - RNA Interference/*physiology
MH  - RNA, Small Interfering
MH  - Transfection
MH  - Polo-Like Kinase 1
EDAT- 2010/11/19 06:00
MHDA- 2011/01/05 06:00
CRDT- 2010/11/19 06:00
PHST- 2010/11/19 06:00 [entrez]
PHST- 2010/11/19 06:00 [pubmed]
PHST- 2011/01/05 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2010 Nov;37(11):2033-41.